First Phase III Results Keep Pfizer's Abrocitinib Among JAK Leaders In Atopic Dermatitis

 
• By Mandy Jackson

Pfizer follows Lilly as the second company to report positive top-line Phase III results in AD for a JAK inhibitor. Safety is a key concern for the class, but Pfizer did not provide any details about abrocitinib's side effects.

Evening scene asphalt international race track with starting or end line, digital imaging recomposition background.
JAK inhbitors are racing to the finish in atopic dermatitis. • Source: Shutterstock

More from Clinical Trials

More from R&D